Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Impact of Diabetes in COVID-19 Associated Mucormycosis and its Management: A Non-Systematic Literature Review

Author(s): Muhammed Rashid, Asha K. Rajan, Girish Thunga, Vishal Shanbhag and Sreedharan Nair*

Volume 19, Issue 3, 2023

Published on: 12 April, 2022

Article ID: e240222201411 Pages: 10

DOI: 10.2174/1573399818666220224123525

Price: $65

Abstract

Background: COVID-19 has become extremely dangerous manifesting itself in a variety of forms ranging from a simple flu-like illness to death. COVID-19 associated mucormycosis (CAM) is a global threat with diabetes being a major contributor.

Objective: This review aims to give a clear picture of the impact of hyperglycemia in CAM along with its management.

Methods: Google and Google Scholar were searched and studies that addressed the impact of diabetes in CAM were considered for this review. We also performed a bibliographic search of the specific article to find additional studies.

Results: A series of events such as unregulated activation of innate immune system modification, pro-inflammatory M1 macrophages activation, and the depletion of natural killer cell activity is very common in patients with COVID-19. In addition, the exacerbated cytokine syndrome and hyperinflammatory response may elevate the severity of this condition, which further leads to higher mortality. The impaired immune phase which follows provide the niche for increased infection among diabetic patients making them more prone towards developing mucormycosis and associated infections. Early detection, surgical debridement, and appropriate medical treatment with antifungals and hypoglycaemic agents may help control the infection and associated morbidity and mortality. COVID-19 drugs, hypoglycaemic agents, antifungals, and comorbidities have all been associated with adverse side effects and drug interactions.

Conclusion: Clinicians should be well aware of this deadly disease and manage COVID-19, diabetes, and mucormycosis through individualized treatment regimens to improve patient outcomes.

Keywords: COVID-19, diabetes, mucormycosis, adverse drug reaction, drug interaction, steroid.

[1]
Khan S, Gionfriddo MR, Cortes-Penfield N, Thunga G, Rashid M. The trade-off dilemma in pharmacotherapy of COVID-19: Systematic review, meta-analysis, and implications. Expert Opin Pharmacother 2020; 21(15): 1821-49.
[http://dx.doi.org/10.1080/14656566.2020.1792884] [PMID: 32752970]
[2]
Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021; 16(3): e0247461.
[http://dx.doi.org/10.1371/journal.pone.0247461] [PMID: 33661992]
[3]
Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: A review of multi-target drugs. Molecules 2020; 25(8): E1987.
[http://dx.doi.org/10.3390/molecules25081987] [PMID: 32340373]
[4]
Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of diabetes 2017. J Diabetes Res 2018; 2018: 3086167.
[http://dx.doi.org/10.1155/2018/3086167] [PMID: 29713648]
[5]
Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (Covid-19) Associated Mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021; 186(2): 289-98.
[http://dx.doi.org/10.1007/s11046-021-00528-2] [PMID: 33544266]
[6]
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16: S27-36.
[7]
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8(9): 782-92.
[http://dx.doi.org/10.1016/S2213-8587(20)30238-2] [PMID: 32687793]
[8]
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020; 14(4): 303-10.
[http://dx.doi.org/10.1016/j.dsx.2020.04.004] [PMID: 32298981]
[9]
Cai J, Li H, Zhang C, et al. The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19. Cell Metab 2021; 33(2): 258-269.e3.
[http://dx.doi.org/10.1016/j.cmet.2021.01.002] [PMID: 33421384]
[10]
Merk VM, Phan TS, Brunner T. Regulation of tissue immune responses by local glucocorticoids at epithelial barriers and their impact on interorgan crosstalk. Front Immunol 2021; 12(672808): 672808.
[http://dx.doi.org/10.3389/fimmu.2021.672808] [PMID: 34012456]
[11]
Revannavar SM. P S S, Samaga L, K K V. COVID-19 triggering mucormycosis in a susceptible patient: A new phenomenon in the developing world? BMJ Case Rep 2021; 14(4): e241663.
[http://dx.doi.org/10.1136/bcr-2021-241663] [PMID: 33906877]
[12]
Erener S. Diabetes, infection risk and COVID-19. Mol Metab 2020; 39: 101044.
[http://dx.doi.org/10.1016/j.molmet.2020.101044] [PMID: 32585364]
[13]
Hernández JL, Buckley CJ. StatPearls Publishing 2021; LLC: 2021.
[14]
Finelli C. Mucormycosis, COVID-19 and diabetes: A framework of situation. EC Clin Med Case Rep 2021; 4(8): 52-3.
[15]
Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13(2): 236-301.
[http://dx.doi.org/10.1128/CMR.13.2.236] [PMID: 10756000]
[16]
S Sarvestani A. Pishdad G, Bolandparvaz S. Predisposing factors for mucormycosis in patients with diabetes mellitus; an experience of 21 years in southern Iran. Bull Emerg Trauma 2013; 1(4): 164-70.
[PMID: 27162850]
[17]
McNulty JS. Rhinocerebral mucormycosis: Predisposing factors. Laryngoscope 1982; 92(10 Pt 1): 1140-3.
[PMID: 7132514]
[18]
Bhadada S, Bhansali A, Reddy KS, Bhat RV, Khandelwal N, Gupta AK. Rhino-orbital-cerebral mucormycosis in type 1 diabetes mellitus. Indian J Pediatr 2005; 72(8): 671-4.
[http://dx.doi.org/10.1007/BF02724075] [PMID: 16131772]
[19]
Steinbrink JM, Miceli MH. Mucormycosis. Infect Dis Clin North Am 2021; 35(2): 435-52.
[http://dx.doi.org/10.1016/j.idc.2021.03.009] [PMID: 34016285]
[20]
Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, et al. Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis 2014; 2014: 562610.
[http://dx.doi.org/10.1155/2014/562610] [PMID: 25210515]
[21]
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of Mucormycosis: An update. J Fungi (Basel) 2020; 6(4): E265.
[http://dx.doi.org/10.3390/jof6040265] [PMID: 33147877]
[22]
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25(1): 26-34.
[http://dx.doi.org/10.1016/j.cmi.2018.07.011] [PMID: 30036666]
[23]
Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362(9398): 1828-38.
[http://dx.doi.org/10.1016/S0140-6736(03)14904-5] [PMID: 14654323]
[24]
Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine 2020; 24: 100433.
[http://dx.doi.org/10.1016/j.eclinm.2020.100433] [PMID: 32766542]
[25]
Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41(5): 634-53.
[http://dx.doi.org/10.1086/432579] [PMID: 16080086]
[26]
Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: Another challenge for India amidst the second wave? Lancet Respir Med 2021; 9(8): e77.
[http://dx.doi.org/10.1016/S2213-2600(21)00265-4] [PMID: 34090607]
[27]
Mishra Y, Prashar M, Sharma D. Akash, Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr 2021; 15(4): 102196.
[http://dx.doi.org/10.1016/j.dsx.2021.102196] [PMID: 34246939]
[28]
Suthananthan AE, Koek SA, Sieunarine K. Cutaneous mucormycosis in an immunocompromised patient: A case report. J Surg Case Rep 2017; 2017(3): rjx056.
[http://dx.doi.org/10.1093/jscr/rjx056] [PMID: 28458862]
[29]
Otto WR, Geoghegan S, Posch LC, et al. The epidemiology of severe acute respiratory syndrome coronavirus 2 in a pediatric healthcare network in the United States. J Pediatric Infect Dis Soc 2020; 9(5): 523-9.
[http://dx.doi.org/10.1093/jpids/piaa074] [PMID: 32559282]
[30]
Quah W, Gunavathy M. Orbital apex syndrome: An unusual complication of invasive mucormycosis. Proc Singapore Healthc 2018; 27(4): 287-9.
[http://dx.doi.org/10.1177/2010105818758089]
[31]
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42(264): e5-8.
[32]
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146.
[http://dx.doi.org/10.1016/j.dsx.2021.05.019] [PMID: 34192610]
[33]
Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 2015; 53(3): 248-57.
[http://dx.doi.org/10.1093/mmy/myu086] [PMID: 25587084]
[34]
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021; 135(5): 442-7.
[http://dx.doi.org/10.1017/S0022215121000992] [PMID: 33827722]
[35]
Kubin CJ, Loo AS, Cheng J, et al. Antimicrobial stewardship perspectives from a New York City hospital during the COVID-19 pandemic: Challenges and opportunities. Am J Health Syst Pharm 2021; 78(8): 743-50.
[http://dx.doi.org/10.1093/ajhp/zxaa419] [PMID: 33543233]
[36]
Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog 2017; 13(8): e1006408.
[http://dx.doi.org/10.1371/journal.ppat.1006408] [PMID: 28771587]
[37]
Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg 2021; 20(3): 1-8.
[http://dx.doi.org/10.1007/s12663-021-01532-1] [PMID: 33716414]
[38]
Dexamethasone/methylprednisolone/prednisolone: Rhino-orbital-cerebral mucormycosis and off-label use: 5 case reports. Reactions Weekly 2021; 1843(1): 137-8.
[http://dx.doi.org/10.1007/s40278-021-91239-2]
[39]
Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: An important but overlooked problem. Endocrinol Metab (Seoul) 2017; 32(2): 180-9.
[http://dx.doi.org/10.3803/EnM.2017.32.2.180] [PMID: 28555464]
[40]
Langhoff E, Ladefoged J. Relative immunosuppressive potency of various corticosteroids measured in vitro. Eur J Clin Pharmacol 1983; 25(4): 459-62.
[http://dx.doi.org/10.1007/BF00542111] [PMID: 6653640]
[41]
Jeronimo CMP, Farias MEL, Val FFA, et al. Metcovid Team. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021; 72(9): e373-81.
[http://dx.doi.org/10.1093/cid/ciaa1177] [PMID: 32785710]
[42]
Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control? Diabetes Care 2020; 43(7): 1408-15.
[http://dx.doi.org/10.2337/dc20-0723] [PMID: 32430456]
[43]
Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses 2021; 64(12): 1452-9.
[http://dx.doi.org/10.1111/myc.13338] [PMID: 34133798]
[44]
Liang Y, Chen X, Wang J, Guo C, Liu F, Yang J. Oral posaconazole and bronchoscopy as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia patient: A case report. Medicine (Baltimore) 2021; 100(6): e24630.
[http://dx.doi.org/10.1097/MD.0000000000024630] [PMID: 33578579]
[45]
Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: A tale of two pathogens. Indian J Ophthalmol 2021; 69(2): 244-52.
[http://dx.doi.org/10.4103/ijo.IJO_3774_20] [PMID: 33463566]
[46]
Bellazreg F, Hattab Z, Meksi S, et al. Outcome of mucormycosis after treatment: Report of five cases. New Microbes New Infect 2014; 6: 49-52.
[http://dx.doi.org/10.1016/j.nmni.2014.12.002] [PMID: 26137308]
[47]
Hamill RJ. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs 2013; 73(9): 919-34.
[http://dx.doi.org/10.1007/s40265-013-0069-4] [PMID: 23729001]
[48]
Shariati A, Moradabadi A, Chegini Z, Khoshbayan A, Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. Infect Drug Resist 2020; 13: 2329-54.
[http://dx.doi.org/10.2147/IDR.S254478] [PMID: 32765009]
[49]
Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23(8): 769-73.
[http://dx.doi.org/10.1097/01.inf.0000134314.65398.bf] [PMID: 15295229]
[50]
KSHFWD. Technical Guideline on diagnosis and treatment of COVID-19 associated mucormycosis (CAM). In: Department HaFW 2021; 1-9. Available from: https://health.kerala.gov.in/pdf/Guidelines_Mucormycosis_management.pdf
[51]
Umpierrez GE, Hellman R, Korytkowski MT, et al. Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97(1): 16-38.
[http://dx.doi.org/10.1210/jc.2011-2098] [PMID: 22223765]
[52]
Lakhani OJ, Kumar S, Tripathi S, Desai M, Seth C. Comparison of two protocols in the management of glucocorticoid-induced hyperglycemia among hospitalized patients. Indian J Endocrinol Metab 2017; 21(6): 836-44.
[http://dx.doi.org/10.4103/ijem.IJEM_226_17] [PMID: 29285445]
[53]
Youngs J, Low JM, Whitney L, et al. Safety and efficacy of intermittent high-dose liposomal amphotericin b antifungal prophylaxis in haemato-oncology: An eight-year single-centre experience and review of the literature. J Fungi 2020; 6(4): 385.
[54]
Laniado-Laborín R, Cabrales-Vargas MN, Amphotericin B. Side effects and toxicity. Rev Iberoam Micol 2009; 26(4): 223-7.
[http://dx.doi.org/10.1016/j.riam.2009.06.003] [PMID: 19836985]
[55]
Noor A, Preuss CV, Amphotericin B. 2022 Sep 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022; Jan.
[PMID: 29493952]
[56]
Moghnieh R, Fawaz I, Mugharbil A, Jisr T, Abdallah D, Ibrahim A. Clinical outcome and adverse events associated with empiric and pre-emptive use of amphotericin B lipid complex in a single center in Lebanon. Bone Marrow Transplant 2016; 51(4): 598-600.
[http://dx.doi.org/10.1038/bmt.2015.276] [PMID: 26618549]
[57]
Sharma R, Bairagi S, Das S, Kumar J. Amphotericin B induced hypokalemia in a diabetic patient with rhino-orbitocerebral mucormycosis. Anaesth Pain & Intensive Care 2017; 21(1): 90-93 50.
[58]
Greer ND. Posaconazole (Noxafil): A new triazole antifungal agent. Proc Bayl Univ Med Cent 2007; 20(2): 188-96.
[http://dx.doi.org/10.1080/08998280.2007.11928283] [PMID: 17431456]
[59]
Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: Mechanism of action, clinical efficacy, and resistance. J Fungi 2020; 6(4): 324.
[60]
Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy. Drug Des Devel Ther 2018; 12: 1033-44.
[http://dx.doi.org/10.2147/DDDT.S145545] [PMID: 29750016]
[61]
Miceli MH, Kauffman CA. Isavuconazole: A new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015; 61(10): 1558-65.
[http://dx.doi.org/10.1093/cid/civ571] [PMID: 26179012]
[62]
Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53(2): 95-113.
[http://dx.doi.org/10.1111/j.1439-0507.2009.01820.x] [PMID: 20002883]
[63]
Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. Clin Pharmacol Drug Dev 2017; 6(1): 66-75.
[http://dx.doi.org/10.1002/cpdd.280] [PMID: 27273004]
[64]
Rashid M, Khan S, Datta D, et al. Efficacy and safety of corticosteroids in acute respiratory distress syndrome: An overview of meta-analyses. Int J Clin Pract 2021; Nov; 75(11): e14645.
[http://dx.doi.org/10.1111/ijcp.14645] [PMID: 34310805]
[65]
Rashid M, Ramakrishnan M, Muthu DS, et al. Factors affecting the outcomes in patients with acute respiratory distress syndrome in a tertiary care setting. Clin Epidemiol Glob Health 2022; 100972.
[http://dx.doi.org/10.1016/j.cegh.2022.100972]

Rights & Permissions Print Cite
Article Metrics
31
2
© 2024 Bentham Science Publishers | Privacy Policy